Top 5 Canadian Stocks To Own For 2015

Top 5 Canadian Stocks To Own For 2015: Valeant Pharmaceuticals International Inc(VRX)

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products in the areas of neurology, dermatology, and branded generics. It offers Wellbutrin XL to treat depressive disorders; Xenazine to treat chorea associated with Huntington?s disease; CeraVe to rebuild and repair skin barrier; and Kinerase, a cosmetic product. The company also provides Zovirax ointment to treat initial genital herpes; Xerese to treat recurrent herpes labialis; Elidel to treat atopic dermatitis; and Acanya and Atralin gels to treat acne vulgaris. In addition, it offers Cesamet to treat nausea and vomiting associated with cancer chemotherapy; Tiazac XC to treat hypertension and angina; Wellbutrin to treat depressive illness; Sublinox to treat insomnia; and Lodalis to treat hypercholesterolemia. Further, the company provides Cold-FX to strengthen immune system; Duromine/Metermine for weight loss; Difflam to treat sore throa ts; and Duro-Tuss and Rikodeine to treat dry and chesty cough, as well as various branded generics for treatments, including antibiotics, treatments for cardiovascular and neurological diseases, antifungal medications, and diabetic therapies. Additionally, it offers Bisocard to treat hypertension and angina pectoris; Flucinar, a corticosteroid ointment; and Sachol mouth ulcer gel; Bedoyecta to treat neurotic pain; M.V.I., a hospital dietary supplement for trauma and burns; Tandene to treat fever and headache; Melleril to treat anxiety and depression; and products for therapeutic classes, such as vitamin deficiency, antibacterials, and dermatology. It markets its products in the United States, Canada, Australia, New Zealand, Europe, Latin America, southeast Asia, and South Africa. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. The company was foun! ded in 1960 and is headquartered in M ississauga, Canada.

Advisors' Opinion:

• [By Jayson Derrick]

  This morning, Valeant Pharmaceuticals (NYSE: VRX) reported its second quarter results. The company announced an EPS of $1.91, beating the consensus estimate of $1.90. Revenue of $2.00 billion missed the consensus estimate of $2.04 billion. Net income for the quarter rose to $122.0 million from $10.8 million in the same quarter a year ago, as the company saw an 86 percent growth in revenue driven by strong growth in almost every business category. Same-store organic product sales growth was 4 percent in the quarter, while pro forma organic growth was 8 percent. Europe saw a same-store sales organic growth of 13 percent, Asia saw a same-store sales organic growth of 17 percent and the U.S. contact lens business helped contribute a 12 percent organic growth in the U.S. Valeant also released a presentation detailing its expectations through 2016, assuming it acquires Allergan. (NYSE: AGN) Valeant lowered its 2014 guidance to reflect the impact of a sale of assets to Nestle as th e company unloaded products that compete with Allergan's. Valeant guided toward 2015 sales of $9.3 billion, ahead of the consensus estimate of $8.9 billion. However, Valeant's 2015 EPS guidance of $9.65 was nearly $1 below the consensus estimate. Shares of Valeant lost 6.71 percent, closing at $117.39.

• [By David Williamson]

  Valeant Pharmaceuticals (NYSE: VRX  ) grows through acquisition, mostly through smaller accretive deals. But management had its elephant guns loaded and after missing out on generic drugmaker Actavis bagged its big game via an $8.7 billion buyout of eye-care heavyweight Bausch & Lomb.

• [By Ben Levisohn]

  Shares of Allergan (AGN) has jumped today after the maker of Botox and other drugs beat earnings forecasts and said it would restructure the company as it attempts to fend off a hostile takeover from Valean! t Pharmac! euticals (VRX).

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-5-canadian-stocks-to-own-for-2015-2.html